Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Debt-to-Equity : -1.38 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories Debt-to-Equity?

Rapid Therapeutic Science Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.40 Mil. Rapid Therapeutic Science Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.39 Mil. Rapid Therapeutic Science Laboratories's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-2.74 Mil. Rapid Therapeutic Science Laboratories's debt to equity for the quarter that ended in Jun. 2023 was -1.38.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rapid Therapeutic Science Laboratories's Debt-to-Equity or its related term are showing as below:

RTSL' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.32 Med: -0.99 Max: 1.13
Current: -1.38

During the past 10 years, the highest Debt-to-Equity Ratio of Rapid Therapeutic Science Laboratories was 1.13. The lowest was -5.32. And the median was -0.99.

RTSL's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs RTSL: -1.38

Rapid Therapeutic Science Laboratories Debt-to-Equity Historical Data

The historical data trend for Rapid Therapeutic Science Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Therapeutic Science Laboratories Debt-to-Equity Chart

Rapid Therapeutic Science Laboratories Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-0.99

-0.93

-0.90

-1.44

-1.22

Rapid Therapeutic Science Laboratories Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															-1.20	-1.23	-1.22	-1.33	-1.38

Competitive Comparison of Rapid Therapeutic Science Laboratories's Debt-to-Equity

For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Therapeutic Science Laboratories's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's Debt-to-Equity falls into.

Rapid Therapeutic Science Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rapid Therapeutic Science Laboratories's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.4	+	0.43)	/	-3.141
	=	-1.22

Rapid Therapeutic Science Laboratories's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.398	+	0.388)	/	-2.739
	=	-1.38

Rapid Therapeutic Science Laboratories (OTCPK:RTSL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rapid Therapeutic Science Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201

Website

https://www.rtslco.com

Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.

Executives

Henry Anthony Punzi	director	1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin	director	639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier	10 percent owner	7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr.	director, 10 percent owner, officer: President and CEO	5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson	director, officer: Chief Operating Officer	2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc.	10 percent owner	5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler	director, officer: CFO	2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond	director, officer: CFO	28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson	director, officer: CEO and President	5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130